* Aileron Therapeutics Inc reported a quarterly adjusted loss of 27 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -40 cents. The lone analyst forecast for the quarter was for a loss of 41 cents per share.
* Reported revenue was zero; analysts expected zero.
* Aileron Therapeutics Inc's reported EPS for the quarter was a loss of 27 cents.
* The company reported a quarterly loss of $5.85 million.
* Aileron Therapeutics Inc shares had fallen by 6.5% this quarter and gained 8.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Aileron Therapeutics Inc is 13.00 This summary was machine generated from LSEG data November 15 at 02:07 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.41 -0.27 Beat
Jun. 30 2024 -0.42 -0.45 Missed
Mar. 31 2024 -0.14 -0.86 Missed
Dec. 31 2023 -0.16 -1.54 Missed
Comments